Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?

Dirican A., Varol U., KÜÇÜKZEYBEK Y., ALACACIOĞLU A., Erten C., Somali I., ...More

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.12, pp.4781-4786, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 12
  • Publication Date: 2014
  • Doi Number: 10.7314/apjcp.2014.15.12.4781
  • Journal Name: ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.4781-4786
  • Keywords: Metastatic colorectal cancer, bevacizumab, neutrophil to lymphocyte ratio, response to therapy
  • Dokuz Eylül University Affiliated: Yes

Abstract

Background: The purpose of this study was to analyze the predictive value of neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most from particular treatments like bevacizumab. Materials and Methods: A total of 245 treatment-naive metastatic colorectal cancern (mCRC) patients were retrospectively enrolled and divided into 2 groups: 145 group A patients were treated with chemotherapy in combination with bevacizumab, and 100 group B patients were treated as above without bevacizumab. Results: Group A patients had better median overall survival (OS) and progression-free survival (PFS) (24.0 and 9.0 months) than group B patients (20 and 6.0 months) (p=0.033; p=0.015). In patients with low NLR, OS and PFS were significantly longer in group A patients (27 vs 18 months, p=0.001; 11 vs 7 months, p=0.017). Conclusions: We conclude that NLR, a basal cancer related inflammation marker, is associated with the resistance to bevacizumab-based treatments in mCRC patients.